Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Med Drug Discov. 2020 May 17;6:100046. doi: 10.1016/j.medidd.2020.100046

Fig. 3. Activation of UPR by AUY-922 (1μM) in HuLEC.

Fig. 3.

Western Blot analysis of (A) cATF6 and β-actin (B) pIRE1α and IRE1α (C) pPERK and PERK (D) BiP and β-actin (E) ERO1-Lα and β-actin (F) PDI and β-actin after treatment of HuLEC with VEH (DMSO) or AUY-922 (1μM). The blots represent three independent experiments. Densitometric analysis was performed to evaluate the signal intensity of the proteins of interest. B-actin was used for the normalization of the protein bands, unless otherwise indicated. *P < .05, **P < .01, ***P < .001 vs vehicle (VEH). Means ± SEM.